Aehr Test Systems shares plunge 20% after revenue decline

Aehr Test Systems (AEHR) shares dropped 20% after the semiconductor equipment maker reported a fiscal fourth-quarter revenue decline to $14.1 million from $16.6 million year-over-year, alongside a net loss of $2.9 million, a significant reversal from the prior year's $23.9 million net income. Management attributed order timing delays to tariff-related uncertainty and is maintaining a cautious financial outlook, anticipating order growth across most segments but not reinstating specific guidance.

Analysis

Aehr Test Systems (AEHR) experienced a significant 20% decline in its share price following the release of its fiscal fourth-quarter results, which revealed a clear deterioration in financial performance. The company's revenue fell to $14.1 million from $16.6 million in the prior-year period, and it reported a net loss of $2.9 million, a stark reversal from the $23.9 million in GAAP net income recorded a year earlier. Management directly attributes this underperformance to external pressures, citing "timing-related delays in order placements due to tariff-related uncertainty," with a particular impact noted for the upcoming first quarter. This has led to a cautious corporate outlook, underscored by the decision to withhold specific financial guidance. While the company anticipates order growth across most segments for the fiscal year, it has explicitly flagged the silicon carbide segment as a potential exception, introducing a specific area of concern within its business outlook.

Key Decisions for Investors

• Given the sharp earnings miss, swing to a net loss, and lack of specific guidance, investors should recognize the heightened uncertainty and near-term risk reflected in the 20% stock drop.
• Monitor developments in trade policy and tariffs closely, as management has identified this as the primary cause of order delays and a key variable for the company's performance in the upcoming quarters.
• Pay particular attention to the performance of the silicon carbide segment, as the company's explicit caution on this front suggests it may underperform relative to other business lines.